Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950697 | 0.84 | AOC3 (0.30) | AOC3SMN1; SMN2CYP3A4HTTSMYD2 | |
| SCHEMBL707090 | 0.82 | MAPK1 (0.34) | MAPK1AOC3ALDH1A1ALOX15ESR1 | |
| SCHEMBL15888456 | 0.81 | MAPK1 (0.37) | MAPK1TAAR1ALDH1A1ALOX15SLC6A2 | |
| SCHEMBL79874 | 0.81 | MAPK1 (0.37) | MAPK1TAAR1ALDH1A1ALOX15SLC6A2 | |
| Hydroxyamine SCHEMBL9901947 | 0.80 | ALDH1A1 (0.35) | MAPK1AOC3TAAR1ALDH1A1ALOX15 | |
| SCHEMBL704188 | 0.79 | MAPK1 (0.36) | MAPK1ALDH1A1ALOX15ESR1ESR2 | |
| SCHEMBL20954476 | 0.78 | TAAR1 (0.34) | MAPK1TAAR1ALDH1A1ALOX15SLC6A2 | |
| SCHEMBL18924906 | 0.77 | ALDH1A1 (0.41) | MAPK1AOC3ALDH1A1ALOX15ESR1 | |
| SCHEMBL707572 | 0.77 | MAPK1 (0.34) | MAPK1ALDH1A1ALOX15ESR1ESR2 | |
| SCHEMBL19720997 | 0.77 | MAPK1 (0.34) | MAPK1ALDH1A1ALOX15ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986797-B | Green low-carbon ABS modified material and preparation method thereof | 东莞市国亨塑胶科技有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-117986797-A | Green low-carbon ABS modified material and preparation method thereof | 东莞市国亨塑胶科技有限公司 | 2024-05-07 | — | — | CN | claimed |
| WO-2012076030-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE COMPOUNDS USEFUL IN THE PREPARATION OF EZETIMIBE | PHARMATHEN S.A. (GR) | 2012-06-14 | — | — | WO | claimed |
| US-7022846-B2 | Metabolites of prinomastat and their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-04-04 | — | — | US | claimed |
| US-20040053922-A1 | Metabolites of prinomastat and their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| CN-117986797-B | Green low-carbon ABS modified material and preparation method thereof | 东莞市国亨塑胶科技有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-117986797-A | Green low-carbon ABS modified material and preparation method thereof | 东莞市国亨塑胶科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-10287312-B2 | Cyclic peroxides as prodrugs for selective delivery of agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-14 | — | — | US | disclosed |
| US-9809647-B2 | Neutralizing anti-CCL20 antibodies | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-2675805-B1 | METHOD FOR THE PREPARATION OF CARBAPENAM COMPOUNDS | INST CHEMII ORGANICZNEJ PAN (PL) | 2016-04-13 | — | — | EP | disclosed |
| EP-1231919-B1 | Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors | SLOAN KETTERING INST CANCER (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8884005-B2 | Method for the preparation of carbapenam compounds | Instytut Chemi Organicznej Pan (PL) | 2014-11-11 | — | — | US | disclosed |
| US-5753653-A | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | AGOURON PHARMACEUTICALS, INC. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
| EP-0522000-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| WO-1992021678-A1 | LIPOXYGENASE INHIBITING PYRROLO [1,2a]INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-12-10 | — | — | WO | disclosed |
| US-5140047-A | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1991014674-A2 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4684642-A | BACTERICIDES | PFIZER INC. (US) | 1987-08-04 | — | — | US | disclosed |
| US-4684641-A | BACTERICIDES | PFIZER INC. (US) | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053922-A1 | Metabolites of prinomastat and their synthesis | MMP7, MMP2, MMP3 | MAPK1 1834/4885AOC3 264/4885AGXT 689/4885 |
| US-10287312-B2 | Cyclic peroxides as prodrugs for selective delivery of agents | GPX4, PRDX1, PRDX3 | MAPK1 3944/4885AOC3 306/4885AGXT 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.